Jump Financial LLC Grows Stock Holdings in Omnicell, Inc. $OMCL

Key Points

• Jump Financial LLC increased its stake in Omnicell, Inc. by 63.4% in the first quarter, now holding 63,627 shares valued at approximately $2.22 million.
• Omnicell reported a quarterly EPS of $0.45, surpassing expectations, with a revenue of $290.56 million compared to forecasts of $275.57 million.
• Wells Fargo & Company raised its price target for Omnicell shares to $40.00, reflecting a positive outlook, with a consensus rating of "Moderate Buy" among analysts.

Jump Financial LLC lifted its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 63.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 63,627 shares of the company's stock after acquiring an additional 24,699 shares during the period. Jump Financial LLC owned approximately 0.14% of Omnicell worth $2,224,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in OMCL. Diversified Trust Co boosted its stake in Omnicell by 2.3% during the 1st quarter. Diversified Trust Co now owns 22,660 shares of the company's stock valued at $792,000 after purchasing an additional 513 shares during the last quarter. Bridge City Capital LLC lifted its holdings in shares of Omnicell by 1.6% in the first quarter. Bridge City Capital LLC now owns 40,136 shares of the company's stock valued at $1,403,000 after purchasing an additional 650 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in shares of Omnicell by 4.6% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 15,832 shares of the company's stock valued at $553,000 after buying an additional 696 shares during the last quarter. Johnson Financial Group Inc. bought a new stake in Omnicell during the fourth quarter worth $37,000. Finally, EntryPoint Capital LLC grew its holdings in Omnicell by 21.6% during the first quarter. EntryPoint Capital LLC now owns 6,671 shares of the company's stock worth $233,000 after buying an additional 1,184 shares in the last quarter. Institutional investors and hedge funds own 97.70% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on OMCL shares. Wells Fargo & Company raised their price objective on Omnicell from $37.00 to $40.00 and gave the company an "overweight" rating in a research note on Monday, July 21st. Benchmark dropped their price target on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Bank of America upped their price objective on shares of Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research report on Friday, May 23rd. Piper Sandler decreased their price objective on shares of Omnicell from $57.00 to $55.00 and set an "overweight" rating for the company in a research note on Monday, August 11th. Finally, Wall Street Zen downgraded Omnicell from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 9th. Four research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat, Omnicell presently has a consensus rating of "Moderate Buy" and an average price target of $46.71.

Omnicell Stock Performance

NASDAQ OMCL traded down $0.49 on Tuesday, hitting $32.10. 517,592 shares of the stock traded hands, compared to its average volume of 542,062. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.24 and a current ratio of 1.42. The business's fifty day moving average is $30.21 and its two-hundred day moving average is $31.46. Omnicell, Inc. has a 12 month low of $22.66 and a 12 month high of $55.74. The firm has a market capitalization of $1.47 billion, a price-to-earnings ratio of 64.20, a PEG ratio of 7.12 and a beta of 0.82.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.30 by $0.15. The firm had revenue of $290.56 million for the quarter, compared to analyst estimates of $275.57 million. Omnicell had a return on equity of 4.27% and a net margin of 2.01%.The business's revenue was up 5.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.51 earnings per share. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. As a group, equities analysts anticipate that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.